Oramed Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Oramed Pharmaceuticals Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Oramed Pharmaceuticals has little or no product revenue yet; it used $5m of cash in the twelve months to June 2026. The diluted share count is up 3.8% on a year earlier, which dilutes existing holders. It passes 1 of our 1 financial-health checks.
Our model value for Oramed Pharmaceuticals is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Current signal Net margin expanding: TTM net margin reached 3202.5%, up 1742.8pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
| At fiscal year end | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Share price | $6.72 | $8.06 | $4.61 | $3.10 | $3.25 | $18.35 | $11.21 | $2.15 | $2.66 |
| Market value | $85m | $107m | $69m | $54m | $67m | $522m | $437m | $87m | $113m |
| + Net debt (− = net cash) | $0 | $0 | $0 | $0 | $0 | $0 | −$40m | $42m | −$45m |
| Enterprise value | $85m | $107m | $69m | $54m | $67m | $522m | $397m | $129m | $67m |
| Multiples | |||||||||
| Price / sales | 132.4x | 43.7x | 28.0x | 20.0x | 24.7x | 193.2x | 161.8x | 65.2x | 56.4x |
| Price / earnings | — | — | — | — | — | — | — | 17.2x | 1.8x |
| Price / free cash flow | 18.3x | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
Weak moat
How hard Oramed Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Net income has been a median -14.9% of total assets over 9 years.
Operating margin has been a median -705.1%; its worst year was -1278.4%.
Free cash flow was positive in 0 of 5 years, at a median -562.5% of revenue.
The diluted share count rose 70.7% over five years; stock-based pay has been a median 43.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
Next results: November 12, 2026, after the close. Analysts expect revenue of $0 for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $4.47 | +198% | — | −100% |
In the last 30 days, 0 analysts raised Oramed Pharmaceuticals Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year |
|---|---|
| 60 days ago | $2.31 |
| 30 days ago | $2.31 |
| 7 days ago | $2.31 |
| Now | $4.47 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $0.43 | $1.84 | +327.9% |
| Dec 2025 | $0.00 | $0.25 | 0.0% |
| Sept 2025 | −$0.04 | $1.13 | +2925.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months +79.5%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $1m | $2m | +49.3% |
| P/S multiple | 68.2x | 85.2x | +24.8% |
| Share count | 41m | 43m | −3.7% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
Last 3 years +139.7%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $3m | $2m | −26.0% |
| P/S multiple | 24.5x | 85.2x | +247.5% |
| Share count | 40m | 43m | −6.8% |
Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| ORMP | +237% | −16% | −81% | +5% | +18% | +51% |
| Industry peers (median) | −36% | −57% | −17% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| ORMP | 83% | 42% | 50% | 42% | 50% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| ORMP | −56% | −74% | −87% | −42% | −23% | −25% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 3, 2015: 94% from November 8, 2021 to November 1, 2023. Getting back needed a 1640% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| November 17, 2025 | +6.9% | −1.8% | +11.2% | +30.0% |
| October 24, 2025 | 0.0% | +2.0% | +0.8% | +9.3% |
| November 10, 2022 | +21.6% | +6.5% | +30.6% | +34.6% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY21 Q2 | $2.7M |
| FY21 Q3 | $2.7M |
| FY21 Q4 | $2.7M |
| FY22 Q1 | $2.7M |
| FY22 Q2 | $2.7M |
| FY22 Q3 | $2.7M |
| FY22 Q4 | $2.7M |
| FY23 Q1 | $2.7M |
| FY23 Q2 | $2.7M |
| FY23 Q3 | $2M |
| FY23 Q4 | $1.3M |
| FY25 Q4 | $2M |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY21 Q1 | -0.3% |
| FY21 Q2 | -0.6% |
| FY21 Q3 | -0.5% |
| FY21 Q4 | -0.5% |
| FY22 Q1 | -0.2% |
| FY22 Q2 | 0.0% |
| FY22 Q3 | 0.0% |
| FY22 Q4 | 0.3% |
| FY23 Q1 | 0.3% |
| FY23 Q2 | 0.3% |
| FY23 Q3 | -25.0% |
| FY23 Q4 | -50.4% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY21 Q2 | -738.3% |
| FY21 Q3 | -903.8% |
| FY21 Q4 | -986.6% |
| FY22 Q1 | -1159.0% |
| FY22 Q2 | -1417.4% |
| FY22 Q3 | -1443.5% |
| FY22 Q4 | -1502.0% |
| FY23 Q1 | -1278.4% |
| FY23 Q2 | -996.2% |
| FY23 Q3 | -1070.4% |
| FY23 Q4 | -1176.8% |
| FY25 Q4 | -754.4% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY20 Q2 | -489.1% |
| FY20 Q3 | -462.1% |
| FY20 Q4 | -590.0% |
| FY21 Q1 | -594.7% |
| FY21 Q2 | -645.2% |
| FY21 Q3 | -757.4% |
| FY22 Q4 | -1051.2% |
| FY23 Q1 | -924.5% |
| FY23 Q2 | -707.9% |
| FY23 Q3 | -865.8% |
| FY23 Q4 | -787.2% |
| FY25 Q4 | -457.7% |
| Fiscal year | 2016 Aug 2016 | 2017 Aug 2017 | 2018 Aug 2018 | 2019 Aug 2019 | 2020 Aug 2020 | 2021 Aug 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2025 Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||
| Revenue | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 1 | 2 |
| Gross profit | 0 | 2 | 3 | 3 | — | — | — | — | 0 |
| EBITDA | −10 | −11 | −14 | −15 | −12 | −24 | −41 | −16 | −15 |
| Operating income | −10 | −11 | −14 | −15 | −12 | −24 | −41 | −16 | −15 |
| Net income | −11 | −10 | −13 | −14 | −12 | −23 | −37 | 5 | 64 |
| Diluted EPS | $0.87 | $0.79 | $0.86 | $0.82 | $0.56 | $0.78 | −$0.94 | $0.14 | $1.50 |
| Growth (year on year) | |||||||||
| Revenue | — | +283.2% | −0.3% | +10.4% | +0.3% | −0.3% | 0.0% | −50.4% | +49.3% |
| Net income | — | — | — | — | — | — | — | — | +>999% |
| Diluted EPS | — | — | — | — | — | — | — | — | +971.4% |
| Margins | |||||||||
| Gross margin | 23.6% | 92.4% | — | 96.7% | — | — | — | — | 0.7% |
| EBITDA margin | <−999% | −438.4% | −552.1% | −541.0% | −433.6% | −893.3% | <−999% | <−999% | −748.4% |
| Operating margin | <−999% | −438.6% | −552.3% | −541.3% | −433.8% | −896.2% | <−999% | <−999% | −754.4% |
| Net margin | <−999% | −426.7% | −519.7% | −531.1% | −424.8% | −850.5% | <−999% | 379.7% | >999% |
| Free-cash-flow margin | 724.8% | −237.7% | −598.7% | −479.3% | −462.1% | −797.5% | <−999% | −787.2% | −457.7% |
| Cash flow | |||||||||
| Cash from operations | 5 | −6 | −15 | −13 | −12 | −21 | −28 | −10 | −9 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 5 | −6 | −15 | −13 | −13 | −22 | −28 | −11 | −9 |
| Stock-based pay | 1 | 2 | 2 | 1 | 0 | 3 | 12 | 4 | 6 |
| Free cash flow after stock pay | 4 | −7 | −16 | −14 | −13 | −24 | −40 | −15 | −15 |
| Balance sheet | |||||||||
| Cash | — | — | — | — | — | — | 40 | 9 | 46 |
| Total debt | 0 | 0 | 14 | 12 | — | — | 0 | 51 | 1 |
| Net debt (negative = net cash) | — | — | — | — | — | — | −40 | 42 | −45 |
| Diluted shares | 13m | 13m | 15m | 17m | 21m | 28m | 39m | 41m | 42m |
| Returned to shareholders | |||||||||
| Buybacks | — | — | — | — | — | — | — | — | 5 |
| Total returned | — | — | — | — | — | — | — | — | 5 |
| Quarter | 2023 Q1 Mar 2023 | 2023 Q2 Jun 2023 | 2023 Q3 Sept 2023 | 2023 Q4 Dec 2023 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
| Gross profit | — | — | — | — | 0 | 0 | 0 | 0 |
| EBITDA | −5 | −4 | −3 | −4 | −4 | −2 | −2 | −6 |
| Operating income | −5 | −4 | −3 | −4 | −5 | −2 | −2 | −6 |
| Net income | −3 | −1 | −3 | 13 | −8 | 13 | 48 | 10 |
| Diluted EPS | −$0.08 | −$0.03 | −$0.08 | $0.33 | −$0.19 | $0.31 | $1.13 | $0.24 |
| Growth (year on year) | ||||||||
| Revenue | 0.0% | 0.0% | −100.0% | −100.0% | — | — | — | — |
| Margins | ||||||||
| Gross margin | — | — | — | — | 0.7% | — | — | — |
| EBITDA margin | −776.4% | −554.7% | — | — | −223.5% | — | — | — |
| Operating margin | −782.0% | −562.5% | — | — | −225.0% | — | — | — |
| Net margin | −509.8% | −177.2% | — | — | −382.1% | — | — | — |
| Free-cash-flow margin | −863.1% | −393.8% | — | — | −176.1% | — | — | — |
| Cash flow | ||||||||
| Cash from operations | −6 | −3 | −1 | −1 | −4 | −4 | −2 | −0 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −6 | −3 | −1 | −1 | −4 | −4 | −2 | −0 |
| Stock-based pay | 0 | 2 | 1 | 1 | 2 | 1 | 1 | 2 |
| Free cash flow after stock pay | −6 | −4 | −2 | −3 | −6 | −4 | −2 | −3 |
| Last 12 months unless stated | ORMP | KRSA | MCRB | CLGN | KRRO | VTGN | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $2m | $2m | $2m | $2m | $2m | $3m | $55m |
| Revenue growth, last 12 months | −50.4% | −12.6% | 100.0% | 360.4% | −62.1% | 287.3% | 12.2% |
| Revenue growth, 3-year average | −9.5% | — | −75.6% | — | −53.7% | — | 13.1% |
| Revenue growth, latest quarter | −100.0% | −100.0% | 100.0% | — | −100.0% | 504.9% | 10.2% |
| Gross margin | 0.7% | — | — | 64.8% | — | — | 82.8% |
| Operating margin | −754.4% | −359.2% | <−999% | −484.3% | <−999% | <−999% | −191.1% |
| Operating margin, 3-year average | <−999% | <−999% | <−999% | — | <−999% | <−999% | −365.3% |
| Net margin | >999% | −353.0% | <−999% | −484.6% | <−999% | <−999% | −163.5% |
| Cash from operations / revenue | −457.3% | −234.3% | <−999% | −397.3% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | −457.7% | <−999% | <−999% | −398.4% | <−999% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | −659.0% | — | −900.2% | — | <−999% | <−999% | −313.4% |
| Stock pay / revenue | 299.6% | 16.9% | 487.8% | 42.1% | 391.7% | 162.7% | 20.7% |
| Change in share count | 3.8% | 45.4% | 11.0% | 6.5% | 28.2% | 30.8% | 8.1% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Mercer Global Advisors Inc | $18.3M | 3.8M | 22.7% | ▲ 99.4% |
| Aquamarine Financial (Cayman) Ltd | $12.1M | 2.5M | 15.0% | ▲ 18.9% |
| Gem Investment Advisors, LLC | $9.6M | 2.0M | 11.9% | ▲ 21.9% |
| Blackrock, Inc. | $7.7M | 1.6M | 9.6% | ▲ 1644.3% |
| Murchinson Ltd. | $6.2M | 1.3M | 7.7% | ▼ 1.9% |
| Bml Capital Management, LLC | $4.2M | 866K | 5.2% | ▼ 72.6% |
| Boothbay Fund Management, LLC | $2.8M | 579K | 3.5% | ▼ 3.7% |
| Geode Capital Management, LLC | $2.4M | 501K | 3.0% | ▲ 1962.0% |
| Goldman Sachs Group Inc | $1.2M | 253K | 1.5% | New |
| State Street Corp | $1.2M | 242K | 1.4% | New |
| Rathbones Group PLC | $1.1M | 233K | 1.4% | ▼ 50.0% |
| Vanguard Portfolio Management LLC | $1.1M | 230K | 1.4% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Oramed Pharmaceuticals Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Hexter Joshua COO & CBO | October 1, 2026 | Sell pre-set plan | 30,000 | $4.51 | $135,330 |
| Gabay Avraham Chief Financial Officer | October 1, 2026 | Sell pre-set plan | 20,000 | $4.51 | $90,200 |
| Gabay Avraham Chief Financial Officer | July 1, 2026 | Sell pre-set plan | 73,360 | $4.51 | $330,854 |
| Hexter Joshua COO & CBO | July 1, 2026 | Sell pre-set plan | 137,000 | $4.46 | $611,020 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
No trades in Oramed Pharmaceuticals Inc. disclosed in the last 12 months; 4 earlier trades on record.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
